Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01967719 · ClinicalTrials.gov registry record · NA
Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol)
A NA study, sponsored by Philip Morris Products S.A..
- Completed
- Registry status
- NA
- Development phase
- 64
- Enrollment target
NCT01967719 is a NA study that has completed, run by Philip Morris Products S.A.. The registered enrollment target is 64 participants.
The verdict
NCT01967719, a NA study, has completed, sponsored by Philip Morris Products S.A..
- COMPLETED
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the pharmacokinetic (PK) profiles (rate and amount of nicotine absorbed) after a single use of the THS 2.2 Menthol (mTHS 2.2) compared to a single use of the menthol conventional cigarette (mCC) and nicotine nasal spray (NNS).
Interventions
- OTHER mTHS 2.2
- OTHER mCC
- OTHER NNS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2013-10 |
| Est. Completion | 2014-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01967719
The ClinicalTrials.gov registry entry for NCT01967719 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Philip Morris Products S.A., which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which mTHS 2.2 is the first listed.
NCT01967719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01967719 about?
NCT01967719 is a clinical study titled "Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol)". The primary objective of the study is to evaluate the pharmacokinetic (PK) profiles (rate and amount of nicotine absorbed) after a single use of the THS 2.2 Menthol (mTHS 2.2) compared to a single use of the menthol conventional cigarette (mCC) and nicotine nasal spray (NNS).
What is the current status of trial NCT01967719?
This trial is currently completed. It is a NA study. The enrollment target is 64 participants. The study started on 2013-10. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01967719?
The interventions under investigation include: mTHS 2.2 (OTHER), mCC (OTHER), NNS (OTHER).
Who is sponsoring clinical trial NCT01967719?
This trial is sponsored by Philip Morris Products S.A., which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.